TPIP external R&D expenses — R&D
Insmed TPIP external R&D expenses — R&D increased by 4.8% to $37.34M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 308.0%, from $9.15M to $37.34M. Over 3 years (FY 2022 to FY 2025), TPIP external R&D expenses — R&D shows an upward trend with a 33.9% CAGR.
Analysis
How to read this metric
An increase typically signals accelerated clinical trial activity or preparation for regulatory filings, while a decrease may indicate the completion of major study phases or a strategic shift in development priorities.
Detailed definition
This metric represents the direct, third-party costs incurred specifically for the research and development of the TPIP...
Peer comparison
Comparable to phase-specific clinical trial spending or external R&D allocations for specific drug candidates at other biopharmaceutical companies.
insm_segment_tpip_external_r_d_expenses_research_and_developmentHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $9.81M | $9.81M | $9.81M | $9.81M | $12.55M | $12.55M | $12.55M | $12.55M | $13.78M | $14.77M | $16.64M | $20.75M | $9.15M | $20.65M | $28.75M | $35.65M | $37.34M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +28.0% | +0.0% | +0.0% | +0.0% | +9.8% | +7.2% | +12.6% | +24.7% | -55.9% | +125.6% | +39.3% | +24.0% | +4.8% |
| YoY Change | — | — | — | — | +28.0% | +28.0% | +28.0% | +28.0% | +9.8% | +17.7% | +32.6% | +65.3% | -33.6% | +39.8% | +72.9% | +71.8% | +308.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Insmed's tpip external r&d expenses — r&d?
- Insmed (INSM) reported tpip external r&d expenses — r&d of $37.34M in Q1 2026.
- How has Insmed's tpip external r&d expenses — r&d changed year-over-year?
- Insmed's tpip external r&d expenses — r&d increased by 308.0% year-over-year, from $9.15M to $37.34M.
- What is the long-term trend for Insmed's tpip external r&d expenses — r&d?
- Over 3 years (2022 to 2025), Insmed's tpip external r&d expenses — r&d has grown at a 33.9% compound annual growth rate (CAGR), from $39.22M to $94.20M.
- What does tpip external r&d expenses — r&d mean?
- The amount of money spent on external research and development activities specifically for the TPIP clinical program.